A Randomized, Double-Blind, Placebo-Controlled Phase-I Clinical Study to Evaluate the Tolerability, Safety and PK Profiles of Human interferon alfa 1b inhalation solution in Healthy Adult Subjects after Administration of Single Ascending Doses and Multiple Ascending Doses
Phase:
PHASE1
Details
Lead Sponsor:
Kexing Biopharm Co., Ltd.
Collaborators:
Beijing SSYP Data Technology Development Co.,Ltd. Guoxin Pharmaceutical Technology (Beijing) Co., Ltd. The Third Hospital of Changsha United-Power Pharma Tech（Shanghai）Co., Ltd.